Press "Enter" to skip to content

A systemic review on mupirocin resistance in Staphylococcus aureus: Current status and future prospects

Rajni Prakasha, Amar Garga & Riteshkumar Aryab*
aSchool of Biological Engineering and Life Sciences, Sobhit Deemed University, Uttar Pradesh, India.
bDepartment of Microbiology, Mehsana Urban Institute of Sciences, Ganpat University, Gujarat, India.
Received : 15th November, 2022 ; Revised : 20th December, 2022

Abstract– Gram positive Staphylococcus aureus bacteria have been identified as prevalent pathogen causing mild tissue infections. In the mid of the 20th century, penicillin and methicillin antibiotics had been widely applied to treat S. aureus infection. This widely and ruthless use of these antibiotics resulted into the development of these antibiotic resistant in the Staphylococcus aureus. With the increasing demand to treat MRSA, Mupirocin has become the first choice of treatment for the heath service providers worldwide. This is because it is most effective against MRSA and its decolonization. However, large-scale use of Mupirocin antibiotic has resulted in Mupirocin resistant Staphylococcus aureus (MuRSA). Conjugative plasmid mup A gene which harbors the antimicrobial resistance determinants, mediates higher side Mupirocin resistance in Staphylococcus aureus (HL-MuRSA). Mutation in native ileS gene mediates lower side Mupirocin resistance in Staphylococcus aureus, which has no medically significant. Reduction in the effectiveness of mupirocin against MRSA has resulted in high risk for invasive infection of MRSA, therefore monitoring of MuRSA is critically needed in present scenario. Keeping this in view, we have discussed mupirocin resistance mechanism, pathological and clinical significance and future perspectives in the current review.

Key words: Staphylococcus aureus, Mupirocin, antimicrobial, clinical significance, penicillin

Download Pdf

Be First to Comment

Leave a Reply